Analysis of antibody titers according to anti-SARS-CoV-2 vaccination schedules, assessed through protein S, discriminated according to history of Covid-19 disease, comorbidities, age and sex in San Lorenzo city
DOI:
https://doi.org/10.62486/agmu202321Keywords:
Covid-19, SARS-CoV-2, Protein S, Vaccines, Immune Response, AntibodiesAbstract
The present study analyzes the humoral immune response in 319 inhabitants of San Lorenzo, Argentina, vaccinated with two doses of different anti-SARS-CoV-2 vaccines. The results show that almost all participants developed Anti-S antibodies, with the Sinopharm vaccine being less effective compared to AstraZeneca, Sputnik V and Moderna. The population was divided according to variables such as sex, age, history of Covid-19 and comorbidities, and it was evident that both people with a history of the disease and those with comorbidities had elevated antibody levels. No significant differences in immunogenicity were found with respect to sex or age, confirming a high response in older adults. The main limitation was a fixed cut-off point of 250 U/ml, which prevented detailed comparisons between schemes. This study suggests the effectiveness of all vaccination schedules studied and underlines the need for future research on the durability of the immune response.
References
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med 2020;382:1199-207. https://doi.org/10.1056/NEJMoa2001316.
Ibáñez Guelfenbein C, Torres Torretti JP, Santolaya De Pablo ME. Vacunas SARS CoV-2, estudios en fase III. Rev Chil Infectol 2021;38:88-98. https://doi.org/10.4067/S0716-10182021000100088.
Johns Hopkins University. COVID-19 Dashboard. Johns Hopkins Univ 2023. https://coronavirus.jhu.edu/map.html.
Ashraf O, Virani A, Cheema T. COVID-19: An Update on the Epidemiological, Clinical, Preventive, and Therapeutic Management of 2019 Novel Coronavirus Disease. Crit Care Nurs Q 2021;44:128-37. https://doi.org/10.1097/CNQ.0000000000000346.
Argentina.gob.ar. Salud confirma el primer caso de coronavirus en el país. Argentina.gob.ar 2020. https://www.argentina.gob.ar/noticias/salud-confirma-el-primer-caso-de-coronavirus-en-el-pais.
Honorable Congreso de la Nación Argentina. Plan estratégico para la vacunación contra la Covid-19 en la República Argentina. 2020.
Rovere P, Laurelli A, Díaz A, Dabusti G, Valdez P. Seroprevalencia de anticuerpos anti S1 SARS-COV-2 en trabajadores vacunados con Sputnik V en un hospital público de la ciudad de Buenos Aires. Med BAires 2021;81:895-901.
Prado A, Salas Cris C, Lopez de Armentia R, Vélez A. Evaluación de la respuesta humoral frente a la vacunación Covid-19 del personal de salud del Hospital Sbarra. Sbarra Científica 2021;3.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet 2021;397:671-81. https://doi.org/10.1016/S0140-6736(21)00234-8.
Senado y Cámara de Diputados de la Nación Argentina. Derechos del Paciente en su Relación con los Profesionales e Instituciones de la Salud. 2009.
Senado y Cámara de Diputados de la Nación Argentina. Ley de Protección de los Datos Personales. 2000.
World Medical Association. Declaración de Helsinki: Principios éticos para las investigaciones médicas en participantes humanos. World Med Assoc 2024. https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/ (accedido 31 de octubre de 2024).
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis 2022;22:196-208. https://doi.org/10.1016/S1473-3099(21)00462-X.
Soto A, M C-RF, Pareja-Medina M, Fernandez-Navarro M, Altamirano-Cáceres K, Sierra Chávez E. Evaluation of the humoral response induced by BBIBP-CorV vaccine by determining neutralizing antibodies in peruvian healthcare personnel. Rev Peru Med Exp Salud Publica 2021;38:493-500. https://doi.org/10.17843/rpmesp.2021.384.9244.
Ridao F. Estudio clínico de evaluación humoral con el empleo de la vacuna Sputnik en La Rioja: informe parcial. La Rioja, Argentina: Centro de Investigación en Medicina Traslacional (CIMT) - Ministerio de Salud Pública de La Rioja; 2021.
Knoll MD, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. The Lancet 2021;397:72-4. https://doi.org/10.1016/S0140-6736(20)32623-4.
Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 2020;588:315-20. https://doi.org/10.1038/s41586-020-2700-3.
Published
Issue
Section
License
Copyright (c) 2023 Yasmin González (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
